Drug
Onalespib clinical trials
Also written AT13387.
Includes 1 study of Onalespib lactate.
- studies test it
- 13
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How studies write it
Studies that test it under each name
Studies by the year they started
13 studies that test it; most in 2016 (5)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 5 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 9
National Cancer Institute (NCI) (9) · Astex Pharmaceuticals, Inc. (4)
Often tested with
Tested in the same studies.
Erlotinib (1) · Cisplatin (1) · At-7519 (1) · Abiraterone Acetate (1) · Abiraterone (1) · Crizotinib (1) · Imatinib (1) · Olaparib (1)
Studies
Open first, then newest update. How each study uses onalespib is read from its arms, and is right about nine times in ten.
Testing it · 13
- Erlotinib Hydrochloride and Onalespib Lactate in Treating Patients With Recurrent or Metastatic EGFR-Mutant Non-small Cell Lung CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT02535338Written as Onalespib Lactate
- Onalespib in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck Receiving Radiation Therapy and CisplatinCompletedPhase 1National Cancer Institute (NCI)NCT02381535Written as Onalespib
- Onalespib and CDKI AT7519 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedPhase 1National Cancer Institute (NCI)NCT02503709Written as Onalespib
- Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryTerminatedPhase 1National Cancer Institute (NCI)NCT02097225Written as Onalespib
- A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone AcetateCompletedPhase 1/2Astex Pharmaceuticals, Inc.NCT01685268Written as AT13387
- A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With CrizotinibCompletedPhase 1/2Astex Pharmaceuticals, Inc.NCT01712217Written as AT13387
- Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid TumorsCompletedPhase 1Astex Pharmaceuticals, Inc.NCT00878423Written as AT13387
- A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GISTCompletedPhase 2Astex Pharmaceuticals, Inc.NCT01294202Written as AT13387 and Imatinib
- Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast CancerCompletedPhase 1National Cancer Institute (NCI)NCT02898207Written as Onalespib
- Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast CancerTerminatedPhase 1National Cancer Institute (NCI)NCT02474173Written as Onalespib
- Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCLTerminatedPhase 2National Cancer Institute (NCI)NCT02572453Written as Onalespib
- AT13387 in Adults With Refractory Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT01246102Written as AT13387
- Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast CancerWithdrawnPhase 1National Cancer Institute (NCI)NCT02627430Written as Hsp90 Inhibitor AT13387
Codes
What other systems call onalespib · ClinicalTrials.gg INT005700
- UNII (FDA) Q7Y33N57ZZONALESPIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27287092onalespibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C85454OnalespibOne source FDA
- DrugBank DB06306One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | Q7Y33N57ZZ | ONALESPIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27287092 | onalespib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C85454 | Onalespib | One source FDA |
| DrugBank | DB06306 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.